October 17-21 2015 Baltimore Maryland

RESULTS: Ethnic distribution did not differ in each reproductive category:
39 premenopausal South Asians and 34 Europeans; 10 perimenopausal
South Asians and 14 Europeans; and 42 postmenoapusal South Asians and 39
Europeans. Body fatness variables increased with reproductive ageing to an
almost similar degree in both ethnic groups (p for trend greater than 0.05 for
all associations) without ethnicity modifying the gradient of the associations
between menopausal state and body fatness (p for interaction with ethnicity
greater than 0.05 for all associations). Moderate to vigorous physical activity
and VO2max decreased in a similar fashion across the reproductive stages in
both ethnic groups whereas energy intake remained unchanged. Body
fatness, physical activity and fitness did not differ among the ethnic groups
for each reproductive stage either. Metabolic biomarkers (insulin, total
cholesterol, triglycerides and blood pressure) deteriorated with reproductive
ageing in both ethnic groups in a similar degree. Notably, HbA1c levels
increased to a much greater degree with reproductive ageing in the South
Asians than in the Europeans (p¼0.02 for interaction with ethnicity).
CONCLUSIONS: The increase in HbA1c levels in healthy women
without overt T2DM during menopausal transition was much greater in the
South Asians than in their White counterparts and this discrepancy was not
explained by a greater deterioration in body composition or physical activity
variables along with reproductive ageing.
O-10 Monday, October 19, 2015 12:00 PM
ASSOCIATION BETWEEN POLYCYSTIC OVARY SYNDROME
AND HOT FLASH PRESENTATION DURING THE
MENOPAUSE TRANSITION. O. Yin, a H. A. Zacur, b J. A. Flaws, c
M. S. Christianson. a a Johns Hopkins University School of Medicine,
Lutherville, MD;
b Reproductive Endocrinologist, Lutherville, MD;
c University of Illinois, Urbana, IL.
OBJECTIVE: While polycystic ovary syndrome (PCOS) is the most common
endocrinopathy in reproductive-age women, most research has focused
on young women and the impact of PCOS on the menopause transition remains
poorly understood. This study aims to determine the influence of
PCOS on hot flash presentation in midlife women.
DESIGN: Retrospective cohort study.
MATERIALS AND METHODS: Subjects were recruited from an ongoing
cohort study involving 748 midlife women aged 45-54 from an urban
metropolitan area. Subjects completed detailed questionnaires that included
hot flash symptom and demographic information. Between June 2014 and
March 2015, 656 patients were contacted by telephone. Those who agreed to
participate were screened for history of PCOS using the Rotterdam criteria.
Chi square analysis and Wilcoxon rank sum test were used as needed to compare
subjects with a history of PCOS with other midlife women. Multivariate logistic
regression was performed to identify factors associated with hot flashes at
midlife; odds ratios (OR) with 95% confidence intervals (CI) were calculated.
RESULTS: A total of 453 women (69%) responded to the telephone interview
and 9.3% (n¼42) met diagnostic criteria for PCOS. The remaining 411
were included as controls. Mean PCOS subject age was 48.0 and body mass
index (BMI) was 27.3. The majority of subjects were Caucasian (73%) with a
smaller proportion African American (21%) and other ethnicities (2%).
PCOS and control groups were not statistically different with respect to
age, BMI, race, income, smoking, drinking, physical activity, number of periods
in the last year, and testosterone, progesterone, or estradiol levels.
Multivariate logistic regression analysis demonstrated that PCOS was not
associated with increased odds of hot flash prevalence, frequency, duration,
or severity. Smoking was the only variable that demonstrated an increased association
with experiencing hot flashes (OR 2.0, 95% CI 1.05-3.98).
CONCLUSIONS: A history of PCOS was not associated with increased
hot flashes during the menopause transition in this study. These data suggest
that women with PCOS have similar hot flash presentations in midlife as
compared to the general population. Additional research should continue
to investigate the health and quality of life implications associated with a
history of PCOS in the aging population.
Supported by: 2R01AG018400 - 05A2.
O-11 Monday, October 19, 2015 12:15 PM
ORAL TIBOLONE (2.5 MG) VERSUS TRANSDERMAL ESTRA-
DIOL GEL (0.06%, 2.5 GM) - EFFECTS ON SERUM CALCIUM
AND 25-HYDROXY VITAMIN D3 LEVELS AFTER SURGICAL
MENOPAUSE. S. M. Bhattacharya a A. Jha. b a Obstetrics and Gynecology,
KPC Medical College, Kolkata, India; b Research Associate, West Virginia,
WV.
OBJECTIVE: To compare the effects of oral Tibolone (2.5 mg) and Transdermal
Estradiol gel (0.06%; 2.5g) on serum Calcium and 25-hydroxy
Vitamin D3 levels in surgically postmenopausal women after 6 months of
treatment.
DESIGN: Open label randomized controlled study.
MATERIALS AND METHODS: 144 women (40-52 years of age) with
surgical menopause (duration 3-18 months and done for benign gynecological
causes and having distressing menopausal symptoms) with preset inclusion
and exclusion criteria were randomized in 1:1 ratio, between
01.03 2013 and 30.06.2014 into 2 groups. Prior ethical approval and
informed written consents (from all participants) were obtained. Group A
received Tibolone (2.5mg, daily) orally and Group B received Transdermal
Estradiol gel (0.06%; 2.5 g, daily). The primary outcomes were comparison
of the absolute changes in serum Calcium and 25- hydroxy Vitamin D3
levels following 6 months of treatment between the two groups. Body
mass index (BMI) and blood pressure (systolic, SBP: diastolic, DBP)
were recorded. Serum calcium and 25- hydroxyl vitamin D3 levels were
measured. All parameters were studied at baseline and after 6 months of
treatment. Sample size was calculated based on a pilot study where 6
months treatment with Tibolone increased vitamin D3 level by 4.91
ng/ml (SD ¼ 6.54) and Transdermal estradiol gel increased vitamin D3
level by 2.08 ng/ml (SD ¼ 3.99). It was calculated that a sample size of
58 patients per group would have 80% power and 95% confidence level
with 2-sided test of significance to detect this mean difference between
the two groups. 6 cases in the Group A and 9 cases in the Group B were
lost to follow up after 6 months of treatment.
RESULTS: Intent-to-treat analysis showed that after 6 months of treatment,
effects of the two treatment interventions were identical in the studied
population. In both intervention arms, patients recorded increase in serum
Calcium and Vitamin D3 levels, but the mean differences were not statistically
significant.
CONCLUSIONS: There were no differences in therapeutic effects of oral
Tibolone and Transdermal Estradiol gel on BMI, blood pressure, serum Calcium
and Vitamin D3 levels in surgically postmenopausal women after 6
months of treatment. Effects of the changes in serum Calcium and Vitamin
D3 levels, by either mode of treatment, on bone remodelling in menopausal
women would need more studies.
Support: None.CTRI registration no. - CTRI/2013/02/003341.
O-12 Monday, October 19, 2015 12:30 PM
LONG TERM HORMONE REPLACEMENT THERAPY (HT)
DOES NOT AFFECT POST-MENOPAUSAL TOTAL BODY
COMPOSITION. A. H. Bayer, a K. N. Goldman, b R. Mauricio, a
M. J. Nachtigall, b F. Naftolin, b L. E. Nachtigall. b a NYU School of Medicine,
New York, NY; b Department of Obstetrics & Gynecology, NYU School of
Medicine, New York, NY.
OBJECTIVE: The impact of HT on menopause-related changes in body
composition is not resolved. We sought to evaluate differences in total
body composition in post-menopausal women who had taken HT for an
average of 14 years.
DESIGN: Retrospective cohort study.
MATERIALS AND METHODS: Post-menopausal women (40-100 years)
on HT for a minimum of 6 years in a university-affiliated menopause clinic
underwent annual Dual Energy X-ray Absorptiometry (DXA) from August
2004 to October 2014. Annual DXA scans from untreated post-menopausal
women seen in the same clinic during the same time period were evaluated as
controls. Exclusion criteria included the diagnosis of primary ovarian insufficiency,
DXA data unavailable or incomplete, and DXA scan not performed
while on HT (for HT group). Primary outcomes were percent (%) total body
fat and % total lean body mass. Secondary outcomes included body mass index
(BMI) and relevant co-morbidities. Data were analyzed using Student’s
t-test and Fisher’s exact test where appropriate (p